65 results on '"Milev, Roumen"'
Search Results
2. Assessing remission in major depressive disorder using a functional-structural data fusion pipeline: A CAN-BIND-1 study
3. Atypical brain aging and its association with working memory performance in major depressive disorder
4. Non-binary gender, vulnerable populations and mental health during the COVID-19 pandemic: Data from the COVID-19 MEntal health inTernational for the general population (COMET-G) study
5. Predicting recurrence of major depressive episodes using the Depression Implicit Association Test: A Canadian Biomarker Integration Network in Depression (CAN-BIND) Report
6. Practices, knowledge, and attitudes about lithium treatment: Results of online surveys completed by clinicians and lithium-treated patients
7. The course of insomnia symptoms during the acute treatment of major depressive disorder: A CAN-BIND-1 report
8. 286. Genetic Polymorphism of Brain-Derived Neurotrophic Factor is Related to Antidepressant Efficacy and Treatment-Induced Hippocampal Plasticity in Patients With Major Depressive Disorder: CAN-BIND-1 Study
9. Data and alternative models describing the associations among non-infection pandemic stress, event-related rumination, depression, and anxiety
10. Alterations in the neural correlates of affective inhibitory control following cognitive behavioral therapy for depression: A Canadian biomarker integration network for depression (CAN-BIND) study
11. EFFECTS OF CYP2C19, CYP2D6, AND ABCB1 GENE VARIANTS ON ESCITALOPRAM AND ARIPIPRAZOLE TREATMENT-RELATED SEXUAL SIDE EFFECTS: RESULTS FROM THE CAN-BIND-1 STUDY
12. Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report
13. The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study.
14. The impact of non-infection pandemic stress on depression and anxiety severity: Investigating mediation by intrusive and deliberate rumination
15. Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report
16. Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report
17. P382. Replication of Personalized Relapse Prediction in Patients With Major Depressive Disorder Using Digital Biomarkers
18. P252. Passive Behavior Sensing Features and Depression Characteristics in a Prospective Relapse Monitoring Study
19. Peripheral Inflammation as a Marker of Response to Sequential Pharmacotherapy in Major Depressive Disorder: A CAN-BIND-1 Study
20. Defining Subtypes of Escitalopram Response Using Resting-State fMRI
21. Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report
22. What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines
23. Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report
24. A detailed manual segmentation procedure for the hypothalamus for 3T T1-weighted MRI
25. Results of the COVID-19 mental health international for the general population (COMET-G) study
26. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study
27. Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report
28. Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report
29. Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report
30. Cortisol reactivity to stress predicts behavioral responsivity to reward moderation by sex, depression, and anhedonia
31. A phase 2, double-blind, placeco-controlled study of the safety and efficacy of microbial ecosystem Therapeutic-2 (MET-2) in patients with major depression: Protocol and preliminary results
32. Clinical effectiveness of non-TMS neurostimulation in depression: Clinical trials from 2010 to 2020
33. White matter microstructure in youth at risk for serious mental illness: A comparative analysis
34. Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report
35. Pre-Treatment Resting-State Functional Connectivity Related to Anhedonia and Anxiety are Associated With Antidepressant Response to Escitalopram and Adjunct Aripiprazole
36. Three insights on psychoneuroimmunology of mood disorders to be taken from the COVID-19 pandemic
37. Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study
38. Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers
39. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report
40. M31 IMPACT OF CYP2C19 AND CYP2D6 GENE VARIANTS ON PLASMA LEVELS AND TREATMENT RESPONSE IN PATIENTS RECEIVING ESCITALOPRAM AND ARIPIPRAZOLE FOR MAJOR DEPRESSION: RESULTS FROM THE CAN-BIND-1 COHORT
41. White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study
42. Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study
43. Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants
44. Distinct Network Structure of Depression Symptoms Among Responders and Non-Responders To Antidepressants and Placebo
45. S124. Impact of CYP2C19 and CYP2D6 Genotypes on Clinical Outcomes and Side Effects in Patients Receiving Escitalopram and Aripiprazole for Major Depression: Results From the Can-Bind Cohort
46. F113. Hippocampal Subfield-Specific Sex Differences in Patients With Major Depressive Disorder
47. F107. Cortical Thickness Features Differentiate 16-Week Antidepressant Response Profiles in Major Depressive Disorder
48. Functional competence in major depressive disorder: Objective performance and subjective perceptions
49. S120. Canadian Biomarker Integration Network in Depression (CAN-BIND): Baseline and Follow up Neurocognitive Mediators of Functioning in Major Depressive Disorder (MDD)
50. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.